Chordia Therapeutics (TSE:190A) Long-Term Debt: 円0.00 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
12 GF Score
Price 円79.00
! 2 Warning Signs
View Full Analysis

What is Chordia Therapeutics Long-Term Debt?

Chordia Therapeutics TSE:190A +1.28% 12 Long-Term Debt is 円0.00 Mil as of Feb. 2026. GuruFocus rates TSE:190A with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Chordia Therapeutics's Long-Term Debt for the quarter that ended in Feb. 2026 was 円0.00 Mil.

Chordia Therapeutics  (TSE:190A) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Chordia Therapeutics Long-Term Debt Related Terms

Chordia Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics Long-Term Debt Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Long-Term Debt
0.00 0.00 0.00 0.00 0.00

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
Long-Term Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
TSE:190A
12GF Score
Chordia Therapeutics Inc TSE:190A
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円0.00 Mil mean?
Chordia Therapeutics (TSE:190A) has a Long-Term Debt of 円0.00 Mil as of Feb. 2026.
Is Chordia Therapeutics' Long-Term Debt too high?
Chordia Therapeutics' current Long-Term Debt is 円0.00 Mil. Overall, Chordia Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' Long-Term Debt compare to VRTX and REGN?
Chordia Therapeutics' Long-Term Debt of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Chordia Therapeutics's current Long-Term Debt is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current Long-Term Debt of 円0.00 Mil. The current Long-Term Debt is 円0.00 Mil. Chordia Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current Long-Term Debt is 円0.00 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
12GF Score

Get the complete analysis for TSE:190A

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円79.00
Price